

Ref.: CV/MD/Reg.30_2021-22

October 04, 2021

The General Manager
Department of Corporate Services
BSE Limited
P. J. Towers,
Dalal Street,
Mumbai – 400001.
Scrip Code: 524075

The Manager
Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, Plot No. C-1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400051.
Symbol: ALBERTDAVD

Dear Sir / Madam,

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We wish to inform you that, Placentrex, the human placental extract product, is an old and well-established product of Albert David Limited ("Albert David"). It is used by the Gynecologists for PID (Pelvic Inflammatory Disease) and by Surgeons, Physicians and other doctors for difficult to heal wounds.

Co-Marketing is a well-established strategic process used by "parent companies" to help expand the product reach/market, thus offering the product benefits to a larger number of end users. We at Albert David too have decided to partner with Corona Remedies Private Limited to help take the 'Placenta Products (Placentrex)', with another brand name, to a larger and wider group of end beneficiaries.

With the above objective, Albert David Limited and Corona Remedies Private Limited have entered into a strategic Co-Marketing Agreement on 4th October, 2021.

This is for your information and record.

Thanking you,

Yours faithfully,
For **Albert David Limited**



Chirag A. Vora
Company Secretary & Compliance Officer

Place: Mumbai